<i>In Vitro</i>Release Kinetics of Antituberculosis Drugs from Nanoparticles Assessed Using a Modified Dissolution Apparatus

Gao, Yuan; Zuo, Jieyu; Bou‐Chacra, Nádia Araci; Pinto, Terezinha de Jesus Andreoli; Clas, S.‐D.; Walker, Roderick B.; Löbenberg, Raimar

doi:10.1155/2013/136590

Cited by 68 publications

(40 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike the dialysis bag that had a large membrane surface area, the GBD was able to discriminate differences between release profiles from different formulations (lipid nanocapsules, nanoparticles, liposomes). In another study, Lobenberg et al compared drug release from Rifampicin and Moxifloxacin hydrochloride nanoparticles with the regular dialysis method (dialysis bag) as well as an adaptation of USP I (basket), where a cylinder containing a dialysis membrane at the bottom was attached to the basket shaft [62]. Results from this study showed that modified USP I set-up was more discriminatory in nature and could be attributed to the reduced surface area of the dialysis membrane.…”

Section: Combination Methodsmentioning

confidence: 94%

A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms

D’Souza

2014

Advances in Pharmaceutics

185

147

View full text Add to dashboard Cite

This review summarizes the methods used to study real-time (37 ∘ C) drug release from nanoparticulate drug delivery systems and establish an IVIVC. Since no compendial standards exist, drug release is currently assessed using a variety of methods including sample and separate (SS), continuous flow (CF), dialysis membrane (DM) methods, and a combination thereof, as well as novel techniques like voltametry and turbidimetry. This review describes the principle of each method along with their advantages and disadvantages, including challenges with set-up and sampling. The SS method allows direct measurement of drug release with simple set-up requirements, but sampling is cumbersome. With the CF method, sampling is straightforward but the set-up is time consuming. Set-up as well as sampling is easier with the DM, but it may not be suitable for drugs that bind to the membrane. Novel methods offer the possibility of real-time drug release measurement but may be restricted to certain types of drugs. Of these methods, Level A IVIVCs have been obtained with dialysis, alone or in combination with the sample and separate technique. Future efforts should focus on developing mathematical models that describe drug release mechanisms as well as facilitate formulation development of nano-sized dosage forms.

show abstract

Section: Combination Methodsmentioning

confidence: 94%

A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms

D’Souza

2014

Advances in Pharmaceutics

185

147

View full text Add to dashboard Cite

show abstract

“…Th e system was stirred at 100 rpm and maintained at a temperature of 37 Ϯ 0.5 ° C. At predetermined time intervals, 5 mL of sample was withdrawn and diluted appropriately, and absorbance was measured by UV -visible spectrophotometer (UV 1700, Shimadzu, Japan) at 269 nm for INH and 276 nm for CIP HCl (Rao and Murthy 2000). Various models (Zero-order, First-order, Higuchi model, and Korsmeyer -Peppas model) were applied to determine the mechanism of drug release from the LPN (Gao et al 2013;Arifi n et al 2006;Zhang et al 2010). …”

Section: In Vitro Drug Release Studymentioning

confidence: 99%

Pulmonary delivery of antitubercular drugs using spray-dried lipid–polymer hybrid nanoparticles

Bhardwaj

Mehta

Yadav³

et al. 2015

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The present study aimed to develop lipid-polymer hybrid nanoparticles (LPNs) for the combined pulmonary delivery of isoniazid (INH) and ciprofloxacin hydrochloride (CIP HCl). Drug-loaded LPNs were prepared by the double-emulsification solvent evaporation method using the three-factor three-level Box-Behnken design. The optimized formulation had a size of 111.81 ± 1.2 nm, PDI of 0.189 ± 1.4, and PDE of 63.64 ± 2.12% for INH-loaded LPN, and a size of 172.23 ± 2.31 nm, PDI of 0.169 ± 1.23, and PDE of 68.49 ± 2.54% for CIP HCl-loaded LPN. Drug release was found to be sustained and controlled at lower pH and followed the Peppas model. The in vitro uptake study in alveolar macrophage (AM) showed that uptake of the drugs was increased significantly if administered in the form of LPN. The stability study proved the applications of adding PLGA in LPN as the polymeric core, which leads to a much more stable product as compared to other novel drug delivery systems. Spray drying was done to produce an inhalable, dry, powdered form of drug-loaded LPN. The spray-dried (SD) powder was equally capable of producing nano-aggregates having morphology, density, flowability and reconstitutibility in the range ideal for inhaled drug delivery. The nano aggregates produced by spray drying manifested their aerosolization efficiency in terms of the higher emitted dose and fine particle fraction with lower mass median aerodynamic diameter. The in vivo study using pharmacokinetic and pharmacodynamic approaches revealed that maximum internalization efficiency was achieved by delivering LPN in SD powdered forms by pulmonary route.

show abstract

“…The concentration of MOX and RIF was determined by a reversed-phase HPLC, which was previously published [38]. In Brief the column was a LiChrocart-LiCrospher 100 RP-18, 5 μm stationary phase (Merck, Darmstadt, Germany), the mobile phase consisted of a mixture of methanol and 0.3% v/v triethylamine-0.02 M PBS (pH 3.0) (40:60 v/v) for the analysis of MOX and a 20 μl sample was injected at a flow rate of 0.9 ml/min with UV detection at 295 nm.…”

Section: Quantitative Analysis By Hplc Methodsmentioning

confidence: 99%